Learning from Patients: The Interplay between Clinical and Laboratory Research in AL Amyloidosis

Moshe E. Gatt*, Marjorie Pick

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Primary systemic light chain amyloidosis (AL) is a rare monoclonal plasma cell disorder. Much research has been performed to determine the factors that underly amyloidogenicity. However, there is increasing evidence that the primary clone, and also patient-related factors, influence the mechanism and rate of the process. The lessons learnt from patient care definitely imply that this is not solely due to the deposition of material in the tissues that cause organ injury but amyloid light chain precursors are likely to mediate cellular toxicity. The disease rarity, combined with the lack of in vitro tools, and that multi-organ failure has a wide clinical spectrum, result in investigative challenges and treatment limitations (due to AL patient frailty). All these characteristics make the disease difficult to diagnose and indicate the need to further study its origins and treatments. This review will focus on the various aspects of the amyloidogenic plasma cell clone, as learnt from the patient care and clinics, and its implications on basic as well as clinical trials of AL research. Details regarding the etiology of the plasma cell clone, understanding the diagnosis of AL, and improvement of patient care with specific consideration of the future perspectives of individualized patient therapy will be described.

Original languageAmerican English
Pages (from-to)3-16
Number of pages14
Issue number1
StatePublished - Mar 2022

Bibliographical note

Publisher Copyright:
© 2021 by the authors.


  • AL amyloidosis
  • light chain toxicity
  • plasma cells


Dive into the research topics of 'Learning from Patients: The Interplay between Clinical and Laboratory Research in AL Amyloidosis'. Together they form a unique fingerprint.

Cite this